Key points are not available for this paper at this time.
Endothelial injury is an early event in chronic kidney disease (CKD) leading to renal hemodynamic disorders and even glomerulosclerosis. During this process, both oxidative stress and inflammation originating from injured endothelial cells can initiate pathogenic cell-to-cell interactions via a paracrine mechanism. Accumulating evidence underscores the pivotal role of mitochondrial dysfunction as a crucial mechanism underlying endothelial dysfunction. Lon protease 1 (LONP1) is a mitochondrial protease that plays a key role in maintaining mitochondrial homeostasis; however, its role in endothelial dysfunction-related renal disease is unknown. In CKD patients and mice subjected to 5/6 nephrectomy (5/6Nx), we observed decreased LONP1 expression in glomerular endothelial cells. Interestingly, endothelial cell-specific heterozygous knockout of LONP1 exacerbated glomerulosclerosis and aggravated renal function decline, proteinuria, hypertension and kidney inflammation in 5/6Nx mice. Mechanistically, our results suggest that the loss of LONP1 strikingly increased reactive oxygen species (ROS) levels by promoting the ubiquitination of mitochondrial superoxide dismutase 2 (SOD2); which in turn led to mitochondrial dysfunction and inflammation within endothelial cells. Additionally, the increase in mitochondrial ROS and subsequent production of inflammatory cytokines from damaged endothelial cells further trigger mesangial cell proliferation and podocyte injury, which together result in glomerulosclerosis and CKD progression. Taken together, our findings identify LONP1 as a therapeutic target for balancing glomerular redox, alleviating inflammation, and retarding glomerulosclerosis.
Zhang et al. (Thu,) studied this question.